A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells. It is a rare disease presenting across all ages with either skin or both skin and bone marrow involvement often conferring a poor prognosis. Though localized radiation has been used before, acute leukemia based regimens, remains the treatment of choice for induction of remission. Hematopoietic stem cell transplant, either autologous or allogeneic, is further required for attaining sustained remissions. Recently, a number of targeted therapies and newer drugs have been used as the molecular and genetic understanding of the disease have improved.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Umberto
U
Falcone
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Hassan
H
Sibai
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: Uday.Deotare@uhn.ca.
Uday
U
Deotare
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003713:Dendritic Cells / Q000473:pathology; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D012878:Skin Neoplasms / Q000628:therapy*
Allogeneic hematopoeitic cell transplant; Autologous hematopoeitic cell transplant; Blastic plasmacytoid dendritic cell neoplasm; HyperCVAD